A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06699914
·
clinicaltrials.gov ↗
COMPLETED
Status
438
Enrollment
INDUSTRY
Sponsor class
Conditions
Neovascular Age-Related Macular Degeneration
Sponsor
Novartis Pharmaceuticals